PIK3CA mutations and predicting the therapeutic effects of neoadjuvant chemotherapy in primary breast cancer

Background: PIK3CA mutations are known to be associated with a reduced pathological complete response (pCR) rate in HER2+ breast cancer, but the relationship between PIK3CA mutations and the therapeutic effects of neoadjuvant chemotherapy in hormone receptor (HR) -positive or HR −/HER2− breast cancer is not clear. We herein analyzed PIK3CA mutations in primary breast cancers of patients who had undergone neoadjuvant chemotherapy. We also investigated the associations of these mutations with the therapeutic effects of neoadjuvant chemotherapy.

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: A. Sato, M. Tanabe, Y. Tsuboi, Y. Ito, F. Akiyama, S. Takahashi, Y. Murakami, Y. Seto Tags: POSTERS A: Basic Science and Translational Research Source Type: research